AN INVESTIGATION OF 2'-DEOXYCOFORMYCIN IN THE TREATMENT OF CUTANEOUS T-CELL LYMPHOMA

  • 1 January 1983
    • journal article
    • research article
    • Vol. 61  (2) , 279-282
Abstract
The use of 2''-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF) was investigated. Since DCF has demonstrated an adverse effect in vitro and in vivo on the survival of leukemia T-cell lines, it appeared reasonable to examine its effect in patients with advanced cutaneous T-cell lymphoma. A total of 8 coiurses of DCF were given to the 4 patients. Since this study was part of an ongoing phase I investigation, each patient received a fixed dose (varying from 4 to 10 mg/sq m daily for 3 consecutive days) on a 28-day schedule. One patient had reversible renal insufficiency. Three patients had reversible myelosuppression. Two patients had a complete remission of disease for 7+ and 9+ mo., respectively. Two additional patients had partial remissions for 4 and 9 mo., respectively. Effective antitumor activity in advanced MF can be achieved with DCF at doses that may not be associated with prohibitive toxicity.